Nasal peptide delivery research in Canada investigates the intranasal route as a method for achieving CNS bioavailability of research peptides without systemic injection. The nasal cavity provides a unique pathway to the brain via the olfactory nerve and trigeminal nerve routes, which bypass the blood-brain barrier. Canadian neuroscience and pharmacokinetics researchers study intranasal peptide delivery using compounds like semax and selank to understand absorption mechanisms, olfactory transport kinetics, and CNS distribution following nasal administration.
Olfactory Nerve Transport Research
The olfactory epithelium provides a direct anatomical connection to the olfactory bulb and brain via the olfactory nerve (cranial nerve I). Peptides administered intranasally can be transported along olfactory nerve axons directly to the brain, bypassing the blood-brain barrier. Canadian pharmacokinetics researchers study this olfactory transport mechanism with peptides like semax and selank, which are specifically formulated for intranasal use in research models.
Comparison with Subcutaneous Administration
Canadian researchers compare nasal versus subcutaneous administration of the same peptides to study differences in CNS bioavailability, onset kinetics, and brain regional distribution. Intranasal delivery may provide more direct CNS access for certain peptides, while subcutaneous delivery provides more predictable systemic pharmacokinetics. The comparison informs optimal research administration route selection.
Sourcing Nasal Peptides in Canada
Research-grade semax and selank in nasal formulations are available from EhBuddy Peptides in Canada. Lab-tested for purity. For laboratory research use only.
Intranasal peptide delivery research in Canada is advancing our understanding of non-invasive CNS drug delivery and olfactory-to-brain transport mechanisms for neuropeptide research compounds.
